- Conditions
- Breast Neoplasms
- Interventions
- Placebo, Docetaxel, AG-013736 (axitinib)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Berkeley, California • Montebello, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 112
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- 75 approved agents, COXEN
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Neoplasms
- Interventions
- Axitinib (AG-013736), Sorafenib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 161
- States / cities
- Burbank, California • Downey, California • Glendale, California + 103 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- CLS-AX, Aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fullerton, California + 28 more
- Conditions
- Thyroid Neoplasms
- Interventions
- AG013736
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Aurora, Colorado • Denver, Colorado + 5 more
- Conditions
- Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
- Interventions
- Axitinib
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 17 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 17 more
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
- Interventions
- Sasanlimab, Palbociclib, Axitinib
- Drug
- Lead sponsor
- Stephanie Berg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasm Metastasis
- Interventions
- PF-07265807, Sasanlimab, Axitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Interventions
- Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 323
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 248 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
- Interventions
- Selenomethionine (SLM), Axitinib, Pembrolizumab
- Drug
- Lead sponsor
- Mohammed Milhem
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
- Interventions
- Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 20
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
- Interventions
- Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET), Pembrolizumab
- Drug · Procedure · Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Axitinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Non-Small Cell Lung Cancer, Urothelial Cancer
- Interventions
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Goodyear, Arizona • Phoenix, Arizona + 8 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- axitinib: observational study
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 6
- States / cities
- San Francisco, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
- Interventions
- axitinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Cancer
- Interventions
- Axitinib, Temsirolimus
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Colorectal Neoplasms
- Interventions
- Bevacizumab (avastin), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Antioch, California • Los Angeles, California + 39 more
- Conditions
- Mucosal Melanoma
- Interventions
- Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Harrison, New York • New York, New York
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab, Axitinib
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Albany, New York • New York, New York + 1 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- CRLX101, Bevacizumab, Standard of Care (Investigator Choice)
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 38
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more
- Conditions
- Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer
- Interventions
- Implantable Microdevice (IMD)
- Combination Product
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab, Axitinib, Cabozantinib
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Springdale, Arkansas • Louisville, Kentucky • St Louis, Missouri + 5 more
- Conditions
- Carcinoid Tumor
- Interventions
- Axitinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- San Francisco, California • Tampa, Florida